MX2019010643A - Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2). - Google Patents

Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).

Info

Publication number
MX2019010643A
MX2019010643A MX2019010643A MX2019010643A MX2019010643A MX 2019010643 A MX2019010643 A MX 2019010643A MX 2019010643 A MX2019010643 A MX 2019010643A MX 2019010643 A MX2019010643 A MX 2019010643A MX 2019010643 A MX2019010643 A MX 2019010643A
Authority
MX
Mexico
Prior art keywords
inhibitor
compositions
forms
methods
same
Prior art date
Application number
MX2019010643A
Other languages
English (en)
Other versions
MX393600B (es
Inventor
Li Ying
Xu Jean
L Ruchelman Alexander
Jain Uday
Zou Daozhong
Huang Lianfeng
MALONA John
Pabba Chittari
Han Jianxin
MOLTER Kevin
Original Assignee
Celgene Car Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Car Llc filed Critical Celgene Car Llc
Publication of MX2019010643A publication Critical patent/MX2019010643A/es
Publication of MX393600B publication Critical patent/MX393600B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a formas sólidas de un inhibidor de MK2, composiciones de los mismos, y métodos para usar los mismos.
MX2019010643A 2017-03-16 2018-03-15 Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2). MX393600B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472015P 2017-03-16 2017-03-16
PCT/US2018/022543 WO2018170199A1 (en) 2017-03-16 2018-03-15 Forms and compositions of a mk2 inhibitor

Publications (2)

Publication Number Publication Date
MX2019010643A true MX2019010643A (es) 2019-10-17
MX393600B MX393600B (es) 2025-03-24

Family

ID=63522534

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010643A MX393600B (es) 2017-03-16 2018-03-15 Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).

Country Status (8)

Country Link
US (2) US10882867B2 (es)
EP (1) EP3595658A4 (es)
JP (2) JP2020514360A (es)
CN (1) CN110678178B (es)
AU (1) AU2018236286B2 (es)
CA (1) CA3054823A1 (es)
MX (1) MX393600B (es)
WO (1) WO2018170199A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
EP3596085A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
WO2018170200A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
WO2018170203A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
WO2020236636A1 (en) * 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
CN116670142A (zh) 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000511882A (ja) * 1996-04-12 2000-09-12 ブリストル―マイヤーズ・スクイブ・カンパニー Ａｃｅ阻害剤及び／またはｎｅｐ阻害剤として有用なｎ―ホルミルヒドロキシルアミン化合物
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
US7790712B2 (en) * 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
CN101360750A (zh) * 2005-11-23 2009-02-04 英特芒尼公司 应激活化蛋白激酶系统的调节方法
MX2009014247A (es) 2007-07-16 2010-01-28 Novartis Ag Compuestos heterociclicos utiles como inhibidores de mk2.
WO2011062765A2 (en) * 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
CN102464639A (zh) * 2010-11-16 2012-05-23 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
AU2012244549B2 (en) * 2011-04-21 2017-04-20 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
WO2014011902A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CA2908098A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
WO2014210319A2 (en) * 2013-06-26 2014-12-31 The Trustees Of Columbia University In The City Of New York Inhibitors of plasmodium falciparum equilibrative nucleoside transporter type 1 as anti-parasitic compounds
WO2016032882A1 (en) * 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
RS62017B1 (sr) * 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
EP3242886A4 (en) 2015-01-08 2018-08-29 Moerae Matrix, Inc., Formulation of mk2 inhibitor peptides
WO2018170203A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
EP3596085A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
KR20230044446A (ko) 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법
CN116670142A (zh) 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体

Also Published As

Publication number Publication date
WO2018170199A1 (en) 2018-09-20
EP3595658A4 (en) 2020-11-25
JP2023017840A (ja) 2023-02-07
CN110678178B (zh) 2023-10-03
AU2018236286B2 (en) 2022-02-17
AU2018236286A1 (en) 2019-09-19
MX393600B (es) 2025-03-24
US10882867B2 (en) 2021-01-05
CN110678178A (zh) 2020-01-10
CA3054823A1 (en) 2018-09-20
US20210198276A1 (en) 2021-07-01
EP3595658A1 (en) 2020-01-22
US20200148701A1 (en) 2020-05-14
US11629153B2 (en) 2023-04-18
JP2020514360A (ja) 2020-05-21

Similar Documents

Publication Publication Date Title
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
MX2022007576A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
CL2018001790A1 (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este (divisional solicitud 201602748)
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
MX388018B (es) Anticuerpos anti-pd1 y métodos de uso.
MX2020003857A (es) Anticuerpos anti-tau y uso de los mismos.
CU20190006A7 (es) Composiciones para inhibir masp-3
EA201992177A1 (ru) Композиции на основе нирапариба
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
BR112019012342A2 (pt) anticorpos il-11
BR112019012343A2 (pt) anticorpos il-11ra
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
CR20160419A (es) Nuevos compuestos biciclicos
MX2017014299A (es) Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
MX2020013630A (es) Analogos de rapamicina y usos de los mismos.
MX373818B (es) Composiciones de apilimod y métodos para usar las mismas.
MX2021006977A (es) Anellosomas y metodos de uso.
MX2020001885A (es) Formulaciones de daptomicina.
EP3710546A4 (en) NOVEL SYNTHETIC CAUSTIC COMPOSITION
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
MX2017011218A (es) Composiciones edulcorantes que contienen rebaudiosidos d.
CO2017001389A2 (es) Compuestos de azetidiniloxifenilpirrolidina
DOP2020000104A (es) Métodos de uso y composiciones que contienen dulaglutida